Core Viewpoint - Chuangli Medical (01858) reported a significant increase in both revenue and net profit for the first half of 2025, indicating strong performance driven by stable supply of procurement products and expansion in international markets [1] Company Performance - Revenue for the first half of 2025 reached approximately 488 million yuan, representing a year-on-year growth of 28.27% [1] - Net profit attributable to shareholders was around 114 million yuan, showing a year-on-year increase of 44.85% [1] - The growth in revenue is attributed to stable supply of procurement products and continuous sales growth [1] - The increase in net profit is due to stable supply of procurement products, deepening international market expansion, and internal cost reduction efforts [1] Market Trends - Guojin Securities noted a recovery trend in domestic medical device procurement demand in the first half of 2025, with expectations for gradual performance recovery in the second half [1] - The demand for consumables is closely related to domestic patient treatment needs, showing relatively small overall fluctuations [1] - Leading medical device companies are accelerating their overseas market investments, with a noticeable increase in channel acquisitions in the first half of the year [1] - Many companies reported that their overseas market growth rates significantly outpaced domestic growth, with some leading firms seeing overseas revenue surpass domestic revenue [1]

春立医疗(01858)涨超12%，截至发稿，涨12.17%，报16.68港元，成交额2142.66万港元。 消息面上，春立医疗公布2025年中期业绩，营业收入约4.88亿元，同比增长28.27%；归属于上市公司股 东的净利润约1.14亿元，同比增长44.85%。公告指出，收入增长主要是期内稳定供应集采产品，销量持 续增长。另外公司稳步推进国际市场的开拓工作，出口业务持续攀升。净利增长则主要归因于期内公司 稳定供应集采产品、深度拓展国际市场，推动销量增长；同时内部降本增效，强化核心业务竞争力，内 外并举推动盈利能力稳步提升，实现了净利润的持续增长。 ...

消息面上，春立医疗公布2025年中期业绩，营业收入约4.88亿元，同比增长28.27%；归属于上市公司股 东的净利润约1.14亿元，同比增长44.85%。公告指出，收入增长主要是期内稳定供应集采产品，销量持 续增长。另外公司稳步推进国际市场的开拓工作，出口业务持续攀升。净利增长则主要归因于期内公司 稳定供应集采产品、深度拓展国际市场，推动销量增长；同时内部降本增效，强化核心业务竞争力，内 外并举推动盈利能力稳步提升，实现了净利润的持续增长。 智通财经APP获悉，春立医疗(01858)涨超12%，截至发稿，涨12.17%，报16.68港元，成交额2142.66万 港元。 ...

报告期内，公司实现归属于母公司股东的净利润约人民币1.14亿元，同比增长44.85%，主要系报告期内 公司稳定供应集采产品、深度拓展国际市场，推动销量增长；同时内部节本增效，强化核心业务竞争 力，内外并举推动盈利能力稳步提升，实现了净利润的持续增长。 格隆汇8月29日丨春立医疗(01858.HK)发布公告，截至2025年6月30日止六个月，公司的营业收入为约人 民币4.88亿元，同比增长28.27%，主要系报告期内稳定供应集采产品，销量持续增长。另外公司稳步推 进国际市场的深度开拓工作，出口业务持续攀升所致。 ...

Core Viewpoint - Spring Medical (01858.HK) reported a significant increase in revenue and net profit for the first half of 2025, driven by stable supply of centralized procurement products and expansion into international markets [1] Financial Performance - The company's operating revenue reached RMB 488 million, representing a year-on-year growth of 28.27% [1] - Total profit, net profit attributable to shareholders, and net profit excluding non-recurring gains and losses for the first half of 2025 were RMB 127 million, RMB 114 million, and RMB 106 million, respectively, with year-on-year growth rates of 53.26%, 44.85%, and 61.09% [1] Strategic Initiatives - The company has made comprehensive and in-depth strategic layouts in the high-value orthopedic consumables sector [1] - There is an active effort to expand into related orthopedic fields, seeking advanced technologies and quality products to enrich the product portfolio [1] - The company aims to increase its market share through a series of initiatives, targeting long-term, stable, and sustainable development in the medical field [1]

Core Viewpoint - Spring Medical (01858) reported a significant increase in both revenue and net profit for the first half of 2025, indicating strong operational performance and market expansion efforts [1] Financial Performance - The company's revenue reached approximately 488 million yuan, representing a year-on-year growth of 28.27% [1] - The net profit attributable to shareholders was about 114 million yuan, showing a year-on-year increase of 44.85% [1] - Basic earnings per share stood at 0.3 yuan [1] Growth Drivers - Revenue growth was primarily driven by stable supply of centralized procurement products and continuous increase in sales volume during the reporting period [1] - The company has been steadily advancing its international market expansion, leading to a rise in export business [1] - Net profit growth was supported by stable supply of centralized procurement products, deepening international market penetration, and internal cost reduction and efficiency enhancement [1]

Core Viewpoint - Spring Medical (01858) reported a significant increase in both revenue and net profit for the first half of 2025, indicating strong operational performance and market expansion efforts [1] Financial Performance - The company's revenue reached approximately 488 million yuan, representing a year-on-year growth of 28.27% [1] - Net profit attributable to shareholders was about 114 million yuan, showing a year-on-year increase of 44.85% [1] - Basic earnings per share stood at 0.3 yuan [1] Revenue Growth Drivers - Revenue growth was primarily driven by stable supply of centralized procurement products and continuous increase in sales volume during the reporting period [1] - The company has been steadily advancing its international market expansion, leading to a rise in export business [1] Profitability Improvement - The increase in net profit was attributed to stable supply of centralized procurement products and deepening international market expansion, which boosted sales [1] - Internal cost reduction and efficiency enhancement measures were implemented to strengthen core business competitiveness, contributing to steady improvement in profitability [1]